Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer

Breast Cancer Research and Treatment

Volumn 133, Issue 3, 2012, Pages 1115-1123

  Lamond, Nathan W D ^a   Skedgel, Chris ^b   Rayson, Daniel ^a,b   Lethbridge, Lynn ^a   Younis, Tallal ^a,b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

21 RS assay; Adjuvant chemotherapy; Breast cancer; Cost utility analysis; Economic evaluation

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; TAMOXIFEN;

21 GENE RECURRENCE SCORE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; BREAST CANCER; CANADA; CANCER PROGNOSIS; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIAGNOSTIC KIT; DRUG COST; DRUG UTILIZATION; FEBRILE NEUTROPENIA; FEMALE; HEALTH CARE SYSTEM; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; POPULATION RESEARCH; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MARKOV CHAINS; NEOPLASM STAGING; QUALITY-ADJUSTED LIFE YEARS;

EID: 84863723973     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-1989-5     Document Type: Article

References (59)

1. Burstein HJ, Prestrud AA, Seidenfeld J et al (2010) American society of clinical oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784-3796
2. Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736-1747
3. Carlson RW, Allred DC, Anderson BO et al (2009) Breast cancer-clinical practice guidelines in oncology. J Natl Compr Cancer Netw 7:122-192
4. Barron JJ, Quimbo R, Nikam PT, Amonkar MM (2008) Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat 109:367-377
5. Broekx S, Den Kond E, Torfs R et al (2011) The costs of breast cancer prior to and following diagnosis. Eur J Health Econ 12: 311-317
6. Dowsett M, Goldhirsch A, Hayes DF, Senn HJ, Wood W, Viale G (2007) International web-based consultation on priorities for translational breast cancer research. Breast Cancer Res 9:R81
7. Harris L, Fritsche H, Mennel R et al (2007) American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312
8. Paik S, Shak S, Tang G et al (2004) A multigene assay to predict the recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826
9. Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734
10. Albain KS, Barlow WE, Shak S et al (2010) Prognostic and predictive value of the 21-gene recurrence score assay in post-menopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55-65
11. Lo SS, Mumby P, Norton J et al (2010) Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 28:1671-1676
12. Oratz R, Paul D, Cohn AL, Sedlacek SL (2007) Impact of a commercial reference laboratory test recurrence score on decision making in early-stage breast cancer. J Oncol Pract 3:182-187
13. Hornberger J, Cosler LE, Lyman GH (2005) Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in Lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care 11:313-324
14. Lyman GH, Cosler LE, Kuderer NM, Hornberger J (2007) Impact of a 21-gene RT-PCR Assay on treatment decisions in early-stage breast cancer: an economic analysis based on prognostic and predictive validation studies. Cancer 109:1011-1018
15. Kondo M, Hoshi SL, Ishiguro H, Yoshibayashi H, Toi M (2008) Economic evaluation of 21-gene reverse transcriptase-polymer-ase chain reaction assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer in Japan. Breast Cancer Res Treat 112(1):175-187
16. Cosler LE, Lyman GH (2009) Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer. Cancer Investig 27:953-959
17. Tsoi DT, Inoue M, Kelly CM, Verma S, Pritchard KI (2010) Cost-effectiveness analysis of recurrence score-guided treatment using a 21-gene assay in early breast cancer. The Oncologist 15:457-465
18. Klang SH, Hammerman A, Liebermann N, Efrat N, Doberne J, Hornberger J (2010) Economic implications of 21-gene breast cancer risk assay from the perspective of an israeli-managed health-care organization. Value Health 13:381-387
19. Kondo M, Hoshi S, Yamanaka T, Ishiguro H, Toi M (2011) Economic evaluation of the 21-gene signature (Oncotype DX) in lymph node-negative/ positive, hormone receptor-positive early-stage breast cancer based on Japanese validation study (JBCRG-TR03). Breast Cancer Res Treat 127:739-749
20. Snow S, Rayson D, Barnes PJ, Sellon M, Thompson K, Younis T. (2008) Does Her2/neu status affect adjuvant chemotherapy utilization? A population based analysis. Poster Presentation at the American Society of Clinical Oncology Breast Cancer Symposium: Washington, DC. Sept 2008
21. Ademuyiwa FO, Miller A, Edge SB et al (2011) The effects of oncotype DX recurrence scores on chemotherapy utilization in a multi-institutional breast cancer cohort. Breast Cancer Res Treat 126(797):802
22. Habel LA, Shak S, Jacobs MK et al (2006) A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 8:R25
23. Kamal AH, Loprinzi CL, Reynolds C et al (2007) How well do standard prognostic criteria predict oncotype DX (ODX) scores? J Clin Oncol 25:18s
24. Asad J, Jacobson AF, Estabrook MD et al (2008) Does oncotype DX recurrence score affect the management of patients with early-stage breast cancer? Am J Surg 196:527-529
25. Erb C, Fox KR, Patel M, et al. (2007) Evaluation of practice patterns in the treatment of node-negative, hormone-receptor positive breast cancer patients with the use of the Oncotype DX assay at the University of Pennsylvania. Presented at the 30th Annual San Antonio Breast Cancer Symposium. December 13-16, 2007; San Antonio, TX. Abstract #3082
26. Klang S, Liebermann N, Rizel L et al (2010) The recurrence score and chemotherapy treatment in node-positive, ER? early-stage breast cancer patients in Israel (Abstract). J Clin Oncol 28:15s
27. Early Breast Cancer Trialists' Collaborative Group [EBCTCG] (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365:1687-1717
28. Statistics Canada. Life Tables-Canada, provinces and territories, 1995-1997. Cat. No. 84-537. Government of Canada. 2003 Statistics, Canada
29. Smith RE, Bryant J, DeCillis A, Anderson S (2003) Acute myeloid leukemia and myelodysplastic syndrome after doxor-ubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the national surgical adjuvant breast and bowel project experience. J Clin Oncol 21:1195-1204
30. Younis T, Rayson D, Sellon M, Skedgel C (2008) Adjuvant chemotherapy for breast cancer: a cost-utility analysis of FEC-D vs. FEC 100. Breast Cancer Res Treat 111:261-267
31. Younis T, Rayson D, Skedgel C (2012) The cost utility of adjuvant chemotherapy with docetaxel and cyclophosphamide compared with adriamycin and cyclophosphamide in breast cancer. Curr Oncol 18(6):e288-e296
32. Diamandidou E, Buzdar AU, Smith TL, Frye D, Witjaksono M, Hortobagyi GN (1996) Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclopho-sphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol 14:2722-2730
33. Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869-2879
34. Towns K, Bedard PL, Verma S (2008) Matters of the heart: cardiac toxicity of adjuvant systemic therapy for early-stage breast cancer. Curr Oncol 15:S16-S29
35. Skedgel C, Rayson D, Dewar R et al (2007) Cost-utility of adjuvant hormone therapies for breast cancer in post-menopausal women: sequential tamoxifen-exemestane and upfront anastraz-ole. Breast Cancer Res Treat 101:325-333
36. Younis T, Rayson D, Dewar R et al (2007) Modeling for cost effective adjuvant aromatase inhibitor strategies for post-meno-pausal women with breast cancer. Ann Oncol 18:293-298
37. Skedgel C, Rayson D, Younis T (2009) The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-posi-tive breast cancer: an analysis based on updated results from the HERA trial. Value Health 12:641-648
38. Bonneterre J, Roche H, Kerbrat P et al (2005) Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French adjuvant study group 05 randomized trial. J Clin Oncol 23:2686-2693
39. Roche H, Fumoleau P, Spielman M et al (2006) Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 24:5664-5671
40. Will BP, Berthelot JM, Le Petit C, Tomiak EM, Verma S, Evans WK (2000) Estimates of the lifetime costs of breast cancer treatment in Canada. Eur J Cancer 36:724-735
41. Tufts-New England Medical Center, Institute for Clinical Research and Health Policy Studies: The CEA Registry. Available at https://research.tufts- nemc.org/cear/Default.aspx. Cited 5 Aug 2010
42. Tengs TO, Wallace A (2000) One thousand health-related qual-ity-of-life estimates. Med Care 38:583-637
43. Ward S, Simpson E, Davis S, Hind D, Rees A, Wilkinson A (2007) Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation. Health Technol Assess 11:1-144
44. Lachaine J, Yelle L, Kaizer L, Dufour A, Hopkins S, Deuson R (2005) Chemotherapy-induced emesis: quality of life and economic impact in the context of current practice in Canada. Support Cancer Ther 2:181-187
45. Dranitsaris G, Tran TM, McGeer A, Narine L (1995) Pharma-coeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients. Pharmacoeconomics 7:49-62
46. Launois R, Reboul-Marty J, Henry B, Bonneterre J (1996) A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics 10:504-521
47. Kasteng F, Sobocki P, Svedman C, Lundkvist J (2007) Economic evaluations of leukemia: a review of the literature. Int J Technol Assess Health Care 23:43-53
48. Levy AR, Briggs AH, Demers C, O'Brien BJ (2001) Cost-effectiveness of beta-blocker therapy with metoprolol or with carvedilol for treatment of heart failure in Canada. Am Heart J 142:537-543
49. Barr R, Furlong W, Henwood J et al (1996) Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy. J Clin Oncol 14:1413-1420
50. Sullivan PW, Ghushchyan V (2006) Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Mak 26:410-420
51. Statistics Canada. Consumer Price Index (Health Care). Available at http://cansim2.statcan.ca/cgi-win/cnsmcgi.exe?Lang=E&RootDir =CII/&ResultTemplate=CII/CII-pick&Array-Pick=1&ArrayId=32 6-0002. Cited 1 Aug 2010
52. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG (2000) Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Mak 20:332-342
53. Mason H, Baker R, Donaldson C (2008) Willingness to pay for a QALY: past, present and future. Expert Rev Pharmacoecon Outcomes Res 8:575-582
54. Meropol NJ, Schrag D, Smith TJ et al (2009) American society of clinical oncology guidance statement: the cost of cancer care. J Clin Oncol 27:3868-3874
55. Greenberg D, Earle C, Fang CH, Eldar-Lissai A, Neumann PJ (2010) When is cancer care cost-effective? A systematic over view of cost-utility analyses in oncology. J Natl Cancer Inst 102:82-88
56. Sridhara R, Johnson JR, Justice R, Keegan P, Chakravarty A, Pazdur R (2010) Review of oncology and hematology drug product approvals at the US food and drug administration between July 2005 and December 2007. J Natl Cancer Inst 102: 230-243
57. Murray CJ, Evans DB, Acharya A, Baltussen RM (2000) Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ 9:235-251
58. Vanderlaan BF, Broder MS, Chang EY, Oratz R, Bentley TGK (2011) Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer. Am J Manag Care 17:455-464
59. Zujewski JA, Kamin L (2008) Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol 4:603-610